Earnings Preview: West Pharmaceutical Services (WST) Q1 Earnings Expected to Decline
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
West Pharmaceutical: Remains A Strong Long-Term Prospect
West Pharmaceutical Services has faced a challenging year, underperforming against the index, with declining volumes, margins, and returns, but remains a strong long-term investment. The company's high-value products segment, driven by GLP-1 medications and biologics, is expected to boost margins and returns significantly. Despite poor timing in share buybacks and management concerns, West's valuation suggests a potential 12.8% annual return, making it a buy.
West Pharmaceuticals Takes A Plunge, But May Still Offer Opportunities
The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction.
Final Trade: WST, BTC, GLD, ALT
The final trades of the day with the Fast Money traders.
Is WST Stock Undervalued At $200?
West Pharmaceutical Services, a global provider of solutions for drugs, biologics, gene therapies, and consumer healthcare products, recently announced its Q4 results, surpassing analysts' expectations for both revenue and earnings. The company reported sales of $749 million and adjusted earnings per share of $1.82, compared to $740 million and $1.73, respectively.
West Pharmaceutical Services, Inc. (WST) Q4 2024 Earnings Call Transcript
West Pharmaceutical Services, Inc. (NYSE:WST ) Q4 2024 Earnings Conference Call February 13, 2025 9:00 AM ET Company Participants John Sweeney - Vice President of Investor Relations Eric Green - Chairman, President & Chief Executive Officer Bernard Birkett - Senior Vice President & Chief Financial Officer Conference Call Participants Michael Ryskin - BofA Global Research Lawrence Solow - CJS Securities Patrick Donnelly - Citigroup Inc. Paul Knight - KeyBanc Capital Markets Matthew Larew - William Blair & Company Justin Bowers - Deutsche Bank David Windley - Jefferies Jacob Johnson - Stephens Inc. Operator Thank you for standing by and welcome to West Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
West Pharmaceutical Stock Sinks On Weaker Than Expected 2025 Guidance
On Thursday, West Pharmaceutical Services, Inc. WST reported a fourth-quarter adjusted EPS of $1.82, beating the consensus of $1.72.
West Pharmaceutical forecasts 2025 results below expectations, shares drop
West Pharmaceutical Services forecast full-year profit and revenue below Wall Street estimates on Thursday due to a strong dollar and as the medical equipment maker's clients reduce inventory levels, sending its shares down 18% premarket.
West Pharmaceutical Services (WST) Surpasses Q4 Earnings and Revenue Estimates
West Pharmaceutical Services (WST) came out with quarterly earnings of $1.82 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.83 per share a year ago.
Will Segmental Performance Drive West Pharmaceutical's Q4 Earnings?
West Pharmaceutical Services WST is scheduled to release fourth-quarter 2024 results on Feb. 13, before the opening bell. In the last reported quarter, the company delivered an earnings beat of 22.52%.
Reasons to Hold West Pharmaceutical Stock in Your Portfolio Now
WST continues to gain momentum due to its strength in the Pharma market unit. However, the decline across its Generics and Biologics business units is concerning.
LH vs. WST: Which Stock Is the Better Value Option?
Investors interested in Medical - Dental Supplies stocks are likely familiar with Labcorp (LH) and West Pharmaceutical Services (WST). But which of these two companies is the best option for those looking for undervalued stocks?
